BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, inhibits mast cell degranulation and has been approved for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma [48,49].